Sequencing Radium-223 and Lutetium-177 PSMA Therapy in mCRPC Management: Insights from the RaLu Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxB7-H4-Targeting Antibody-Drug Conjugate, LNCB74, Gets Green Light for Clinical Trials for Solid Tumors
/0 Comments/in Clinical Trial, Phase 1/by MaxNew Drug Receives FDA Clearance to Begin Clinical Trials
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxA New Dawn for Disease Treatment: Combining mRNA and RNAi Therapies
/0 Comments/in CRISPR, Preclinical Research/by MaxNewsletter 4
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Here I am with the fourth newsletter from the site. In the next days I will be reporting some (hopefully) good news from an immune oncology symposium, fingers crossed! Some of the subscribers suggested me to reactivate the donations button, do you […]
Matching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/0 Comments/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxMapping the Gut: A New Atlas Illuminates the Path to Understanding and Treating Cancer (and other diseases)
/0 Comments/in Not PCa related, Preclinical Research/by MaxPreclinical: A More Efficient and Selective Path to Anti-Cancer Drugs
/0 Comments/in Preclinical Research/by MaxTags
abiraterone acetate ADC ADT androgen deprivation therapy antibody-drug conjugate apalutamide ATM bispecific antibody cancer cancer immunotherapy cancer treatment CAR-T castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer oncology PARP inhibitor PEACE-1 personalized medicine prostate cancer PSA response PSMA radioligand therapy real-world data small molecule survival outcomes T-cell therapy targeted drug delivery theranostics tumor microenvironment
Latest Posts
- Newsletter 3/2025 January 19, 2025
- PARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair January 18, 2025
- Update on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025 January 17, 2025
- UMass Scientists Develop Novel Bacteria-Based Cancer Therapy January 16, 2025